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Abstract
Overexposure to endocrine disruptor chemicals (EDCs) can result in serious health 
problems, yet they are commonly found in everyday items such as pesticides, personal 
care products, nutritional supplements, and plastics. The U.S. Environmental Protection 
Agency, along with other such agencies from around the world, have therefore man-
dated that new approaches be designed to screen these products for the presence of 
EDCs. However, despite the presence of several types of extant EDC detection assays, 
there still exists a backlog approaching 87,000 chemicals currently awaiting screening. 
Autobioluminescent detection systems, which utilize cellular bioreporters capable of 
autonomously modulating bioluminescent signals without the need for external stimula-
tion or investigator interaction, provide an attractive means for addressing this backlog 
because of their reduced performance costs and increased throughput relative to alterna-
tive assay systems. This chapter reviews the variety of existing EDC detection assays and 
evaluates the performance of a representative autobioluminescent estrogen-responsive 
EDC bioreporter to provide an overview of how autobioluminescence can be used to 
improve EDC detection using in vitro assay systems.
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1. Introduction
The human endocrine system is an interconnected, finely tuned network of glands that pro-
duce hormones responsible for health and well-being from the time of conception until death. 
Chemicals classified as endocrine disruptors (EDCs) interfere with the production, release, 
transport, and/or action of these hormones and cause imbalances that are suggested to result 
in significant negative health impacts such as infertility, premature puberty, obesity, diabetes, 
heart disease, and breast, prostate, testicular, thyroid, endometrial, and ovarian cancers [1]. 
These chemicals, which are present in a variety of sources including pesticides, cosmetics, and 
plasticizers, number in the tens of thousands (Figure 1) [2].
The potential adverse effects of EDCs on human, wildlife, and ecosystem health have received 
significant worldwide attention from the scientific community, regulatory agencies, and the 
general public. Unfortunately, the uncertainties inherent to understanding the true health 
consequences of EDC exposure have fostered significant controversy, and the lay person is 
besieged with an extensive collection of ‘facts’ when attempting to grasp the fundamental 
content of the EDC problem. One only needs to Google bisphenol-A (BPA) to appreciate the 
informational complexity surrounding a chemical suspected of being an endocrine disruptor. 
Capitalizing on the difficulties posed by this situation, a multitude of companies have formed 
to evaluate how the compounds that make up everyday items such as pesticides, personal 
care products, nutritional supplements, and plastics can imbalance the delicate regulation of 
normal endocrine function in humans and wildlife.
There are currently over 500 contract testing service companies in the U.S. alone that are dedi-
cated to performing assays for the chemical, pesticide, and personal care products industries, 
and this industry is expected to continue growing year-over-year at an annual rate of 13.5% [3]. 
Figure 1. Tens of thousands of chemicals are suspected of having the potential to interfere with the endocrine system, 
resulting in adverse health effects in people and wildlife.
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To improve throughput and decrease costs, these companies have adapted a two-tiered 
screening format, with Tier 1 consisting of in vitro assays aimed at identifying those chemicals 
that have the potential to interact with the endocrine system, and Tier 2 re-screening those 
compounds that test positive using in vivo assays to define their endocrine-related effects and 
obtain dosage-relevant information. Unfortunately, despite their societal importance, these 
tests remain biologically, logistically, and economically challenging. Tier 1 testing of chemi-
cals for potential EDC activity is estimated to cost from $100,000 to $250,000 per chemical, with 
Tier 2 testing requiring upwards of 1,200 experimental animals and costing $1.2–$2.5 million 
per chemical [4, 5]. The majority of these costs will be borne by the chemical manufacturing 
industry, which then trickles down as increased prices at the consumer level. Furthermore, 
many of the common Tier 1 assay formats employed by these companies use non-human 
cell lines that can obscure bioavailability data [6, 7], require the use of radioactive materials 
that necessitate dedicated use areas and specially trained personnel [6–8], rely on expensive 
analytical equipment [8, 9], or do not meet the U.S. Environmental Protection Agency’s (EPA) 
full testing requirements [3].
Realizing the deficiencies of these screening programs, and receiving considerable pressure 
from the public to reduce the use of animals for EDC testing, the U.S. EPA, with stakeholder 
input from the NIH National Institute of Environmental Health Sciences (NIEHS), has estab-
lished the Endocrine Disruptor Screening Program for the twenty-first century (EDSP21) [10]. 
The goal of EDSP21 is to replace the current battery of Tier 1 tests with less expensive and 
faster high-throughput assays that can reduce the number of compounds that unnecessarily 
move forward to Tier 2 testing. This focus on improving the characterization of chemicals 
during Tier 1 screening is paramount to controlling costs, as mischaracterizations (i.e., false 
positives) during the Tier 1 stage magnify the costs of downstream Tier 2 screening, with 
a chemical’s progression through multiple phases of Tier 2 screening only to be classified 
as negative for EDC activity representing a very poor return on investment. With the cur-
rent chemical backlog approaching 87,000 chemicals [11], and considering the conventional 
scientifically acceptable false positive error rate of 5%, under current Tier 1 testing formats a 
minimum of 4350 chemicals will likely mistakenly proceed toward Tier 2 screening at a cost 
of approximately $8 billion.
The use of autobioluminescent EDC cellular bioreporters represents an attractive means to 
overcome the limitations of existing Tier 1 screening platforms and address the needs of 
the EDSP21 program. Autobioluminescence, with is defined as the ability to self-initiate the 
production of a luminescent signal using only endogenously supplied substrates to per-
form the enzymatic reactions necessary for signal generation [12], can reduce the number 
of required assay steps, eliminate the need for superfluous reagent costs, maintain human 
bioavailability relevance through the use of human cellular hosts, and increase through-
put by minimizing hands-on performance time and employing automated processing and 
detection systems [13]. These benefits are made possible by the autonomous functionality 
of the synthetic luciferase gene cassette (lux) that controls the autobioluminescent pheno-
type. To enable autonomous EDC detection, lux cassette expression is regulated by a yeast 
upstream activating sequence (UAS), which is itself activated by a hybrid Gal4 transcrip-
tional activator. Expression of this activator is, in turn, governed by the binding of an EDC to 
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an upstream estrogen (ERE; pictured) or androgen (ARE) response element (Figure 2). The 
use of this EDC-responsive promoter system within a human cell can therefore signal EDC 
bioavailability while simultaneously providing information regarding the timing, magni-
tude, and duration of the resulting effect. Using the detection of estrogenic compounds as 
an example, this chapter will provide an overview of how these autobioluminescent cellular 
bioreporters function in this role relative to alternative, traditional Tier 1 EDC sensor plat-
forms and the advantages and disadvantages they provide for addressing the needs of the 
EDSP21 program.
2. Requisite endocrine disrupting chemical detection parameters
The U.S. EPA [14] and the Interagency Coordinating Committee on the Validation of Alternative 
Methods (ICCVAM) [15] have established performance requirements for all EDC detection 
assays. These performance requirements ensure that the assays can function efficiently enough 
to identify the presence of EDCs at levels believed to be impactful to human and environmental 
health. However, rather than mandating that an assay demonstrates predetermined responses 
Figure 2. Functional schematic of an estrogenic compound-responsive autobioluminescent induction system. Step 1: 
Gal4ff expression is induced upon estrogenic compound exposure. Step 2: The lux cassette is then activated through 
stimulation of the UAS/TATA promoter by the Gal4FF transcriptional activator. Androgenic compound induction 
proceeds similarly.
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across all known EDC compounds, these organizations require that the assay respond appro-
priately to treatment with serial dilutions of representative strong, weak, and very weak 
agonists, and that they do not respond to an appropriate negative control. To be considered 
successful, estrogenic detection assays must meet the U.S. EPA metrics presented in Table 1 
and androgenic detection assays must meet the ICCVAM metrics presented in Table 2.
3. Non-autobioluminescent detection assay formats
There are five in vitro assay formats, other than autobioluminescence, that are used for EDSP21 
Tier 1 screening [16] (Table 3). All of these assays are well-established, having been initially 
developed as early as the 1960’s. Although their performance is reproducible and reliable, 
each is subject to a number of detriments that limit their utility for low-cost, high-throughput 
EDC detection with high human relevance [6–9, 14].
For instance, in the estrogen receptor (ER) binding assay, cytosol must be isolated from the 
uteri of rats that have undergone ovariectomy prior to collection of the uterine tissue. These 
animal subjects are ovariectomized 7–10 days before harvesting the uterine tissue, with 
each test chemical requiring the use of approximately 19 subjects. Once the uteri have been 
harvested, they are homogenized and centrifuged to isolate ER-containing cytosol. Before 
conducting the assay, saturation radioligand binding assays using various concentrations 
of radioactively labeled 17β-estradiol added to each batch of cytosol are performed to first 
PC
50
—concentration which induces a response at 50% of the maximal positive control response.
PC
10
—concentration which induces a response at 10% of the maximal positive control response.
EC
50
—half maximal effective concentration.
EC
50
—half maximal effective concentration.
Table 1. EPA guidelines for the successful detection of endocrine disruptor chemicals in human cells.
Table 2. ICCVAM average EC
50
 value guidelines required for the successful detection of androgenic compounds.
Rapid, High-Throughput Detection of Endocrine Disrupting Chemicals Using…
http://dx.doi.org/10.5772/intechopen.78378
131
validate that there are sufficient ER concentrations and to confirm that the receptor is func-
tioning with appropriate affinity. Only after this series of preliminary steps are the actual 
assays run. During the assay, radioactively labeled 17β-estradiol, uterine cytosol, and test 
chemical are combined and must undergo a 16–20 h incubation at 4°C in the dark. Following 
incubation, hydroxyapatite is added, and multiple washings are performed before a final elu-
tion with ethanol and measurement of radioisotope activity in a liquid scintillation counter 
[7]. Similarly, the complementary androgen receptor (AR) binding assay follows the same 
intricate assay steps as the ER binding assay, but begins with the collection of rat ventral 
prostate tissues using subjects that are castrated ~24 h prior to assay initiation. Similar to the 
ER binding assay, this inclusion of approximately 19 animal subjects per test chemical results 
in increased moral, economical, and logistical concerns [6].
Like the ER and AR binding assays, the aromatase assay also uses radioactively labeled 
chemicals as detection targets. In addition, assay performance also requires the use of con-
trolled substances, and therefore necessitates specialized waste disposal. Although these 
attributes do not directly hinder assay performance, they add cost and increase the logistical 
hurdles underlying assay execution. However, the tradeoff for the use of these chemicals is 
an increased throughput. Under standard conditions, the aromatase assay can be completed 
with only 6–8 person hours per run. This makes the aromatase assay a more attractive format 
for companies concerned with personnel costs. Another advantage of the aromatase assay is 
that it uses human recombinant microsomes as the detection vehicle, which provides addi-
tional human bioavailability relevance compared with the use of animal tissues in the ER and 
AR binding assays [8].
Unlike the above-mentioned assays, the steroidogenesis assay uses a human adrenocor-
tical carcinoma cell line as its detection vehicle, which provides direct information on the 
human-relevant effects of compound exposure. However, while this represents a significant 
advantage, it also comes with the drawback that the cells must remain exposed to the test 
Table 3. The five traditional in vitro tier 1 EDC detection assays used in EDSP21.
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chemical for 48 h, making this one of the longer duration assay formats. Further complicat-
ing the throughput of the assay is the detection method, which uses liquid chromatography 
positive atmospheric pressure photoionization tandem mass spectroscopy (LC/APPI-MS/MS) 
to measure the hormone concentrations in the medium as the assay endpoint. While this pro-
vides exquisite levels of sensitivity, the equipment required to perform these measurements is 
relatively expensive and requires highly-skilled technical personnel for operation. This limits 
the performance of this assay format to only those labs large enough to justify the associated 
operational costs [9].
The estrogen receptor transactivation assay (ERTA), also uses a human cell line as its detection 
vehicle. In this case, the assay leverages a human cervical cancer cell line containing a firefly 
luciferase reporter gene that emits a bioluminescent signal when chemicals bind to and activate 
the estrogen receptor. The bioluminescent output of this format makes it an attractive option 
because it does not require specialized equipment or skilled personnel to perform. The cells for 
this assay are simply plated in microtiter plates, the test chemical is added, and the plates are 
incubated for 20–24 h. Following incubation, the luciferase assay reagent is then added to each 
well to lyse the cells, and bioluminescence is measured. While this assay format is among the 
most simplistic to perform, the multi-day performance period and the need for requisite sample 
destruction concurrent with the addition of an exogenous activation chemical impart concerns 
relating to throughput, performance costs, and the potential interaction of the activating chemi-
cal with the compound under study. Nonetheless, the ETRA remains a popular choice for EDC 
detection due to its many advantages relative to the alternative assay formats [14].
4. Autobioluminescent detection assay formats
4.1. Advantages
Autobioluminescent assays systems address the backlogging problems endemic to EDSP21 
because they utilize human cellular hosts as their detection vehicles, their signal generation is 
fully performed by these host cells without the need for external stimulation, their resulting 
reporter signal does not require cellular destruction or interfere with cellular metabolism, they 
are capable of self-regulating bioluminescent production throughout EDC exposure, and they 
maintain the same output format (luminescent production) as the commonly used ERTA [13]. 
Because these same output and detection vehicle formats are maintained, autobioluminescent 
assay systems share the advantages of providing direct human bioavailability information 
and not requiring specialized equipment or skilled personnel to perform. However, unlike 
the ERTA, the bioreporter cells used in autobioluminescent assays do not require lysis and 
therefore remain viable for an unlimited number of repeated or fully continuous measure-
ments. This allows cytotoxicity measurements to be taken on control wells within each plate 
at any time point desired and eliminates the need for duplicate plate preparation. Since all 
data are obtained in real-time, the assay intervals employed in autobioluminescent assays can 
be shortened or lengthened on-the-fly based on the results being obtained, which provides 
an increased level of flexibility when working with previously uncharacterized compounds 
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(Figure 3). In addition, the detection equipment used to perform the ERTA can be used to per-
form autobioluminescent assays, so no change in equipment infrastructure is required [17].
This continuous imaging ability of autobioluminescence provides higher levels of data acqui-
sition than the alternative assay formats and is more amenable to high-throughput use. This 
results in a significant cost savings of approximately 87% per assay relative to the ERTA, which 
has the lowest performance costs of the alternative assay types. For example, under moderate 
throughput conditions a 96-well microtiter test plate can be used to accommodate triplicate 
replicates of four test chemicals and their associated controls. Using this testing format, it 
would require 21,750 96-well plates to characterize the existing backlog of 87,000 chemicals 
that are pending under EDSP21 [11]. Based on existing market costs for technician time and 
chemical reagents [18, 19], it would cost approximately $1.5 billion (USD) to process all of 
these compounds. However, the reduced performance costs of the autobioluminescent assay 
format, which result primarily from a reduction in technician hands-on time and removal of 
the need to purchase an activating chemical substrate, reduces these costs to approximately 
$191,000 (USD), representing a savings of approximately $1.3 billion (USD).
4.2. Performance and EDC detection abilities
To evaluate the utility of autobioluminescence’s repeated interrogation approach, autobiolu-
minescent T47-D cells were seeded in triplicate into multi-well plates and incubated under 
standard growth conditions for 24 h. After this time, the medium was removed, cells were 
washed once with phosphate buffered saline (PBS), refreshed with EDC-free medium, and 
Figure 3. (A) The continuous signal generation of autobioluminescent assays allows for uninterrupted, real-time, high-
throughput monitoring of cell activity across consecutive time points. This increases flexibility relative to (B) the ERTA, 
which only generates single time point snapshots of cellular activity.
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supplemented with 17β-estradiol at concentrations of 0 pM (control), 0.1 pM, 1 pM, 10 pM, 
100 pM, 1 nM, 10 nM, or 100 nM. Autobioluminescent measurements were then obtained 
every 24 h for 6 days using an IVIS Lumina imaging system with a 10 min integration time. 
Increased autobioluminescent signals relative to untreated control cells were observed by 
day 3 for all treatments ≥1 pM, although this trend was only maintained throughout the full 
6 day assay period at treatment levels ≥10 pM. A dose–response relationship was observed 
between 17β-estradiol treatment levels and autobioluminescence, with an EC
50
 value of 10 pM 
(Figure 4). Similar results were obtained using the alternative MCF-7 breast cancer cell line, 
which could detect 17β-estradiol at concentrations of both 1 and 10 nM through the signifi-
cant (p < 0.05) induction of an autonomously-regulated autobioluminescent signal compared 
to both background light detection and the signal generated cells treated only with vehicle 
controls (Figure 5A).
Notably, the autobioluminescent production from both of these breast cancer cell lines dis-
played a relatively low signal-to-noise ratio, likely due to their natural expression of estrogen 
receptors and EDC transporters. To overcome this limitation, the system was re-created in 
the naturally ER-negative HEK293 human kidney cell line and co-transfected with human 
estrogen receptor alpha. This allowed for expression of the system without interference 
from native EDC uptake and processing pathways and significantly reduced the level of 
background autobioluminescent production in the absence of EDC stimulation, as well as 
Figure 4. Using repeated measurements of T47-D breast cancer cell line samples, the autobioluminescent assay format 
allowed dose/response relationships between autobioluminescence and EDC treatment levels to be determined for each 
day that showed a significant increase compared to negative control cells.
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increasing the signal-to-noise ratio during positive detection events (Figure 5B). Using this 
system design, EDC-responsive autobioluminescent HEK293 bioreporters were able to detect 
an array of representative EDCs at levels relevant to the requirements of EDSP21 (Table 4).
This bioreporter similarly proved to be effective for the detection of other commonly encoun-
tered EDCs, such as synthetic hormones, synthetic industrial compounds, phytoestrogens, 
and fungicides (Table 5). These detection capabilities are especially promising given that the 
autobioluminescent system can be scaled to allow for robotic integration. This would allow cell 
plating, dosing, and reading to be fully automated. Since the addition of exogenous substrate 
or sample manipulation post-treatment is not required, this system reduces assay complexity 
and facilitates rapid detection using automated systems. Given its advantages relative to the 
existing assay formats (Table 6), autobioluminescence represents an attractive alternative assay 
for potential high-throughput Tier 1 screening of the EPA’s current chemical inventory list.
Figure 5. (A) An autobioluminescent MCF-7 cell line was capable of fully autonomous 17β-estradiol detection but 
displayed a low signal-to-noise ratio. (B) Re-created HEK293 cell line expressing human estrogen receptor alpha and the 
autobioluminescent reporter construct allowed for fully autonomous 17β-estradiol detection with an improved signal-
to-noise ratio.
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5. Future directions and recommendations
While autobioluminescent assays have the potential to significantly improve the throughput 
and cost effectiveness of Tier 1 EDC detection, they are currently in their infancy. Of the tested 
methods, only the HEK293-based autobioluminescent assay format was capable of produc-
ing data with similar performance metrics to the incumbent screening procedures. It is clear 
that the utility of the autobioluminescent assay format will need to expand to additional cell 
types and to the detection of androgenic compounds in order to fully address the bioavail-
ability and health effects of EDCs. Similarly, while this work screened the performance of 
Table 4. When expressed in HEK293 cells, the estrogen compound-responsive autobioluminescent reporter system 
detected an array of representative EDCs within the EPA detection guidelines.
Table 5. The autobioluminescent HEK293-based estrogenic compound-responsive bioreporter was found to be an 
efficient and simplistic means for the detection of a wide variety of compounds with known estrogenic effects.
Table 6. Summary of the observed advantages and disadvantages of the autobioluminescent EDC detection format 
relative to alternative tier 1 screening methods.
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the HEK293-based estrogen-responsive bioreporter against a variety of EDCs and associated 
controls, it will be necessary to validate the performance of this assay format at the levels 
of scale required for commercial use. Therefore, the development of additional bioreporter 
cell types and their validation at scale using automated assay preparation, performance, and 
detection equipment is recommended as a next step in the maturation of this assay format. 
If autobioluminescent assays can perform reliably under these conditions while maintaining 
a similar level of performance to that observed from the HEK293-based estrogen-responsive 
bioreporter, they will prove a valuable tool for Tier 1 EDC detection.
6. Conclusions
Tier 1 in vitro assays are the front line in EDC detection. However, the limitations of tradi-
tional assay formats, which use non-human cell lines that can obscure bioavailability data [6, 
7], require the use of radioactive materials that necessitate dedicated use areas and specially 
trained personnel [6–8], or rely on expensive analytical equipment [8, 9], are currently incapa-
ble of handling the sheer number of compounds that must be screened. Autobioluminescent 
assays, such as the HEK293-based estrogen-responsive bioreporter assay presented here, are 
uniquely positioned to overcome the limitations of existing assay formats by autonomously 
generating bioluminescence in response to target chemical or chemical class bioavailability. 
The use of these reporter systems allows bioluminescent responses to be linked to EDC detec-
tion for reagent-free, fully automated screening at a fraction of the cost of existing assays, pro-
viding a promising route toward addressing the existing EDC compound screening backlog.
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